2. Signaling Pathways
  3. Stem Cell/Wnt
  4. PKG

PKG

 
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1292
    PKG inhibitor peptide
    		99.91%
    PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM.
    PKG inhibitor peptide
  • HY-112197
    PKG drug G1
    		99.11%
    PKG agent G1 targets C42 of PKG Iα. PKG agent G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.
    PKG drug G1
  • HY-P1556A
    Vasonatrin Peptide (VNP) TFA
    		98.79%
    Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway.
    Vasonatrin Peptide (VNP) TFA
  • HY-P1292A
    PKG inhibitor peptide TFA
    PKG inhibitor peptide TFA is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM.
    PKG inhibitor peptide TFA
  • HY-P1556
    Vasonatrin Peptide (VNP)
    Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway.
    Vasonatrin Peptide (VNP)
  • HY-137622
    Sp-cGMPS
    		Activator
    Sp-cGMPS is an activator of cGMP-dependent protein kinases (PKGs). Sp-cGMPS can be used in cardiovascular disease-related research.
    Sp-cGMPS
  • HY-135110A
    Rp-8-Br-cGMPS
    		Inhibitor
    Rp-8-Br-cGMPS (Rp-8-bromo-Cyclic GMPS) sodium salt is a potent Ca2+-ATPase activator. Rp-8-Br-cGMPS is also an agonist of the rod CNG channel and an inhibitor of PKG. Rp-8-Br-cGMPS sodium salt mediates cytosolic Ca2+ reduction by activating Ca2+-ATPase and subsequently removing Ca2+ from the cell.
    Rp-8-Br-cGMPS
  • HY-137373
    Rp-8-pCPT-cGMPS
    		Inhibitor
    Rp-8-pCPT-cGMPS is a competitive inhibitor of cGMP-dependent protein kinase (PKG) (Ki=0.5 μM). Rp-8-pCPT-cGMPS has high lipid solubility and can more easily penetrate the cell membrane and reach sufficient concentration inside the cell to inhibit cGMP-dependent protein kinase. Rp-8-pCPT-cGMPS can be used to study the activity and function of cGMP-dependent protein kinase in platelets.
    Rp-8-pCPT-cGMPS
  • HY-151203
    PKG1α activator 3
    PKG1α activator 3 is a PKG1α activator (EC50 basal/partial=13/0.52 μM). PKG1α activator 3 shows anti-proliferative effects to smooth muscle cell, and can be used in cardiovascular disease research.
    PKG1α activator 3
  • HY-P1561
    PKG Substrate
    		98.05%
    PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG).
    PKG Substrate
  • HY-135110
    Rp-8-Br-cGMPS sodium
    		Inhibitor
    Rp-8-Br-cGMPS (Rp-8-bromo-Cyclic GMPS) sodium salt is a potent Ca2+-ATPase activator. Rp-8-Br-cGMPS is also an agonist of the rod CNG channel and an inhibitor of PKG. Rp-8-Br-cGMPS sodium salt mediates cytosolic Ca2+ reduction by activating Ca2+-ATPase and subsequently removing Ca2+ from the cell.
    Rp-8-Br-cGMPS sodium
  • HY-155106
    SMA4
    SMA4 is a selective PKG1α activator with basal EC50 value of 29 μM. SMA4 facilitates phosphorylation of the known PKG1 substrate, vasodilator-stimulated phosphoprotein (VASP), and inhibits human pulmonary arterial smooth muscle cells (hPASMC) proliferation. SMA4 can be used for cardiovascular disease research.
    SMA4
  • HY-153539
    AP-C3
    		Inhibitor
    AP-C3 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.3. AP-C3 only weakly inhibits cGKII-dependent anion secretion.
    AP-C3
  • HY-110221
    Rp-8-pCPT-cGMPS sodium
    		Inhibitor
    Rp-8-pCPT-cGMPS sodium is the sodium salt form of Rp-8-pCPT-cGMPS. Rp-8-pCPT-cGMPS is an inhibitor for cGMP-dependent protein kinase (cGK). Rp-8-pCPT-cGMPS sodium is an agonist for cyclic nucleotide-gated (CNG) channels in a voltage-dependent manner.
    Rp-8-pCPT-cGMPS sodium
  • HY-153542
    AP-C6
    		Inhibitor
    AP-C6 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C6 concentration-dependently inhibits human cGKII activity in vitro. AP-C6 potentiate cAMP signaling by PDE inhibition.
    AP-C6
  • HY-153541
    AP-C7
    		Inhibitor
    AP-C7 is an inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 5.0. AP-C7 only weakly inhibits cGKII-dependent anion secretion.
    AP-C7
  • HY-153537
    AP-C1
    		Inhibitor
    AP-C1 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C1 only weakly inhibits cGKII-dependent anion secretion.
    AP-C1
  • HY-P10036
    G-Subtide
    G-Subtide is a G-substrate peptide localized in Purkinje cells of the cerebellum. G-Subtide has little activity distinct from background and is a preferentially phosphorylated peptide substrate of recombinant PfPKG2 protein.
    G-Subtide
  • HY-153540
    AP-C4
    		Inhibitor
    AP-C4 is an inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 5.2. AP-C3 does not inhibit cGKII-dependent anion secretion.
    AP-C4
  • HY-131737
    1-NH2-cGMP
    		Activator
    1-NH2-cGMP is an analog of cGMP.
    1-NH2-cGMP
Cat. No. Product Name / Synonyms Application Reactivity